Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma

Immunotherapies are promising approaches for treating hepatocellular carcinomas (HCCs) refractory to conventional therapies. However, a recent clinical trial of immune checkpoint inhibitors (ICIs) revealed that anti-tumor responses to ICIs are not satisfactory in HCC cases. Therefore, it is critical...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishida, Naoshi, Kudo, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281618/
https://www.ncbi.nlm.nih.gov/pubmed/32443599
http://dx.doi.org/10.3390/cancers12051274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281618/
https://www.ncbi.nlm.nih.gov/pubmed/32443599
http://dx.doi.org/10.3390/cancers12051274

Ejemplares similares